Krisztian Homicsko

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


64 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2008 | 2006 | 2005 | 2003 | 2002 | 2001 |
Sous presse
 
Patient-derived mini-colons enable long-term modeling of tumor-microenvironment complexity.
Lorenzo-Martín L.F., Broguiere N., Langer J., Tillard L., Nikolaev M., Coukos G., Homicsko K., Lutolf M.P. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6FBB2EBCBF0E]
2024
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence.
Watson S.S., Zomer A., Fournier N., Lourenco J., Quadroni M., Chryplewicz A., Nassiri S., Aubel P., Avanthay S., Croci D. et al., 2024/09/09. Cancer cell, 42 (9) pp. 1507-1527.e11. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ACA88D313315]
 
Nanoplasmonic Single-Tumoroid Microarray for Real-Time Secretion Analysis.
Liu Y.C., Ansaryan S., Tan J., Broguiere N., Lorenzo-Martín L.F., Homicsko K., Coukos G., Lütolf M.P., Altug H., 2024/09. Advanced science, 11 (34) pp. e2401539. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_854452266478]
 
Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids.
Dutta D., Lorenzo-Martín L.F., Rivest F., Broguiere N., Tillard L., Ragusa S., Brandenberg N., Höhnel S., Saugy D., Rusakiewicz S. et al., 2024/08/14. NPJ precision oncology, 8 (1) p. 179. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7156FDC43C39]
 
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.
König D., Sandholzer M.T., Uzun S., Zingg A., Ritschard R., Thut H., Glatz K., Kappos E.A., Schaefer D.J., Kettelhack C. et al., 2024/07/02. Cancer immunology research, 12 (7) pp. 814-821. Peer-reviewed.
[DOI][Pmid][serval:BIB_43CB67C6DE73]
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N., Fortis E., Spathis A., Anastasiou M., Economopoulou P., Foukas GRP, Lelegiannis I.M., Rusakiewicz S., Vathiotis I., Aung T.N. et al., 2024/04. Annals of oncology, 35 (4) pp. 340-350. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_77EE6FBCAC5B]
iPSC-derived and Patient-Derived Organoids: Applications and challenges in scalability and reproducibility as pre-clinical models
Heinzelmann Elisa, Piraino Francesco, Costa Mariana, Roch Aline, Norkin Maxim, Garnier Virginie, Homicsko Krisztian, Brandenberg Nathalie, 2024. Current Research in Toxicology, 7 p. 100197.
[URN][DOI][WoS][serval:BIB_0D64D95B6A86]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03AE420D2700]
 
A neutrophil response linked to tumor control in immunotherapy.
Gungabeesoon J., Gort-Freitas N.A., Kiss M., Bolli E., Messemaker M., Siwicki M., Hicham M., Bill R., Koch P., Cianciaruso C. et al., 2023/03/30. Cell, 186 (7) pp. 1448-1464.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75BDBCD58180]
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs F.S., Moura B., Missiaglia E., Aedo-Lopez V., Michielin O., Tsantoulis P., Bisig B., Trimech M., Zoete V., Homicsko K., 2023/02/24. International journal of molecular sciences, 24 (5) p. 4520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E3A48A3138B7]
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8<sup>+</sup> T cells and reprogramming macrophages.
Tichet M., Wullschleger S., Chryplewicz A., Fournier N., Marcone R., Kauzlaric A., Homicsko K., Deak L.C., Umaña P., Klein C. et al., 2023/01/10. Immunity, 56 (1) pp. 162-179.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D37AF3A7C808]
2022
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
Gautron Moura B., Gerard C.L., Testart N., Caikovski M., Wicky A., Aedo-Lopez V., Berthod G., Homicsko K., Prior J.O., Dromain C. et al., 2022/12/21. Cancers, 15 (1) p. 31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0AF72365A8C3]
 
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.
Zeng Q., Saghafinia S., Chryplewicz A., Fournier N., Christe L., Xie Y.Q., Guillot J., Yucel S., Li P., Galván J.A. et al., 2022/11/18. Science, 378 (6621) pp. eabl7207. Peer-reviewed.
[DOI][Pmid][serval:BIB_324086550512]
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.
Chryplewicz A., Scotton J., Tichet M., Zomer A., Shchors K., Joyce J.A., Homicsko K., Hanahan D., 2022/10/10. Cancer cell, 40 (10) pp. 1111-1127.e9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D8C0A81E8E9D]
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.
Digklia A., Boughdad S., Homicsko K., Dromain C., Trimech M., Dolcan A., Peters S., Prior J., Schaefer N., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005383. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_923D116CD173]
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Homicsko K., Dummer R., Hoeller C., Wolchok J.D., Hodi F.S., Larkin J., Ascierto P.A., Atkinson V., Robert C., Postow M.A. et al., 2022/05/05. Cancers, 14 (9) p. 2300. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D579FC357B1]
 
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Digklia A., Coukos G., Homicsko K., 2022/05/02. Clinical cancer research, 28 (9) pp. 1745-1747. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0CAC463D4200]
 
Sphingolipids control dermal fibroblast heterogeneity.
Capolupo L., Khven I., Lederer A.R., Mazzeo L., Glousker G., Ho S., Russo F., Montoya J.P., Bhandari D.R., Bowman A.P. et al., 2022/04/15. Science, 376 (6590) pp. eabh1623. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D703E8F69887]
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V., Gérard C.L., Boughdad S., Gautron Moura B., Berthod G., Digklia A., Homicsko K., Schaefer N., Duran R., Cuendet M.A. et al., 2022/02/24. Cancers, 14 (5) p. 1162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F8308EFA619]
2021
 
Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard C.L., Delyon J., Wicky A., Homicsko K., Cuendet M.A., Michielin O., 2021/12. Cancer treatment reviews, 101 p. 102227. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AB33FCA1873]
 
Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.
Saghafinia S., Homicsko K., Di Domenico A., Wullschleger S., Perren A., Marinoni I., Ciriello G., Michael I.P., Hanahan D., 2021/10. Cancer discovery, 11 (10) pp. 2638-2657. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3BABADE6621]
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
Thouvenin L., Charrier M., Clement S., Christinat Y., Tille J.C., Frigeri M., Homicsko K., Michielin O., Bodmer A., Chappuis P.O. et al., 2021/08. Gynecologic oncology reports, 37 p. 100787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB2F51C1A9EA]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
2020
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology.
Krebs F.S., Gérard C., Wicky A., Aedo-Lopez V., Missiaglia E., Bisig B., Trimech M., Michielin O., Homicsko K., Zoete V., 2020/10/28. International journal of molecular sciences, 21 (21) pp. E8021. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_44F221AEB60A]
 
Organoid technology and applications in cancer immunotherapy and precision medicine.
Homicsko K., 2020/10. Current opinion in biotechnology, 65 pp. 242-247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BB24203665BA]
 
High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays.
Brandenberg N., Hoehnel S., Kuttler F., Homicsko K., Ceroni C., Ringel T., Gjorevski N., Schwank G., Coukos G., Turcatti G. et al., 2020/09. Nature biomedical engineering, 4 (9) pp. 863-874. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71E34713FAA0]
Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]
Huber A., Latifyan S., Nikolopoulou A., Homicsko K., Berthod G., Michielin O., Özdemir B.C., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1092-1097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E5DDB348D97F]
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
Frisone D., Charrier M., Clement S., Christinat Y., Thouvenin L., Homicsko K., Michielin O., Bodmer A., Chappuis P.O., McKee T.A. et al., 2020. Cancer biology & therapy, 21 (3) pp. 197-202. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DDF548EFECDC]
 
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F., Schiappacasse L., Levivier M., Tuleasca C., Cuendet M.A., Aedo-Lopez V., Gautron Moura B., Homicsko K., Bettini A., Berthod G. et al., 2020/01. Journal of neuro-oncology, 146 (1) pp. 181-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_18BD1C202E95]
2019
 
Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification.
Özdemir B.C., Bohanes P., Bisig B., Missiaglia E., Tsantoulis P., Coukos G., Montemurro M., Homicsko K., Michielin O., 2019/12. JCO precision oncology, 3 pp. 1-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E12437A0DD54]
 
The Romand Network of Oncology: bridging the gap of personalised oncology
Michielin O., Tsantoulis P., Homicsko K., Christinat Y., De Leval L., Bisig B., Missiaglia E., Zoete V., Krebs F., Fortin A. et al., 2019/10/18. Swiss Medical Weekly.
[serval:BIB_2A3947B3BCE2]
 
Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.
Digklia A., Duran R., Homicsko K., Kandalaft L.E., Hocquelet A., Orcurto A., Coukos G., Denys A., 2019/09. Cardiovascular and interventional radiology, 42 (9) pp. 1221-1229. Peer-reviewed.
[DOI][Pmid][serval:BIB_13E5E5B29D1D]
2018
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 1083 pp. 124-136. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E8B0234B5672]
 
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE6933D4F057]
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
Viala M., Vinches M., Alexandre M., Mollevi C., Durigova A., Hayaoui N., Homicsko K., Cuenant A., Gongora C., Gianni L. et al., 2018/03/06. British journal of cancer, 118 (5) pp. 679-697. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B98F6A7521FE]
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Voruz S., Martins F., Cairoli A., Naveiras O., Homicsko K., Missiaglia E., de Leval L., Bisig B., Michielin O., Blum S., 2018/03. Haematologica, 103 (3) pp. e130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0845E1BF99E5]
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S., Cairoli A., Naveiras O., de Leval L., Missiaglia E., Homicsko K., Michielin O., Blum S., 2018/01. Haematologica, 103 (1) pp. e39-e41. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_12A8F7D8B626]
2017
 
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Stathis A., Hess D., von Moos R., Homicsko K., Griguolo G., Joerger M., Mark M., Ackermann C.J., Allegrini S., Catapano C.V. et al., 2017/12. Investigational new drugs, 35 (6) pp. 766-772. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BBC028AA0E8]
 
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Fankhauser M., Broggi MAS, Potin L., Bordry N., Jeanbart L., Lund A.W., Da Costa E., Hauert S., Rincon-Restrepo M., Tremblay C. et al., 2017/09/13. Science translational medicine, 9 (407) pp. 1-13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C55698C8F509]
2016
 
Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors.
Homicsko K., Duraiswamy J., Doucey M.A., Coukos G., 2016/12/01. Cancer research, 76 (23) pp. 6765-6767. Peer-reviewed.
[DOI][Pmid][serval:BIB_611A58A2720E]
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Wick W., Gorlia T., Bady P., Platten M., van den Bent M.J., Taphoorn M.J., Steuve J., Brandes A.A., Hamou M.F., Wick A. et al., 2016/10/01. Clinical cancer research, 22 (19) pp. 4797-4806. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CBAAFBFE2DD4]
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Dittrich Christian, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas et al., 2016/09. ESMO Open, 1 (5) pp. e000097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FECB702281DB]
Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements.
Homulle H.A., Powolny F., Stegehuis P.L., Dijkstra J., Li D.U., Homicsko K., Rimoldi D., Muehlethaler K., Prior J.O., Sinisi R. et al., 2016. Biomedical Optics Express, 7 (5) pp. 1797-1814. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CD09E0FEA550]
2015
 
The consensus molecular subtypes of colorectal cancer.
Guinney J., Dienstmann R., Wang X., de Reyniès A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P. et al., 2015/11. Nature medicine, 21 (11) pp. 1350-1356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84C36AD6D137]
 
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
Tosi D., Laghzali Y., Vinches M., Alexandre M., Homicsko K., Fasolo A., Del Conte G., Durigova A., Hayaoui N., Gourgou S. et al., 2015/07/01. Journal of clinical oncology, 33 (19) pp. 2158-2165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_558C476141B9]
 
Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]
Moura B., Homicsko K., Berthod G., Cerottini J.P., Guggisberg D., Gaide O., Maillard M.H., Michielin O., 2015/05/20. Revue medicale suisse, 11 (475) pp. 1108,1110-1114.
[Pmid][serval:BIB_5A4B24BBA8FE]
 
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M., Tabatabai G., Kästner B., Felsberg J., Steinbach J.P., Wick A., Schnell O., Hau P., Herrlinger U., Sabel M.C. et al., 2015. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research, 21 (9) pp. 2057-2064. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F937117C954C]
 
Targeting Programmed Cell Death 1 in Ovarian Cancer.
Homicsko K., Coukos G., 2015. Journal of Clinical Oncology, 33 (34) pp. 3987-3989. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A88FF3F32E5C]
2014
 
A community computational challenge to predict the activity of pairs of compounds.
Bansal M., Yang J., Karan C., Menden M.P., Costello J.C., Tang H., Xiao G., Li Y., Allen J., Zhong R. et al., 2014/12. Nature biotechnology, 32 (12) pp. 1213-1222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F647C6B32994]
 
A community effort to assess and improve drug sensitivity prediction algorithms.
Costello J.C., Heiser L.M., Georgii E., Gönen M., Menden M.P., Wang N.J., Bansal M., Ammad-ud-din M., Hintsanen P., Khan S.A. et al., 2014/12. Nature biotechnology, 32 (12) pp. 1202-1212. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71822A472839]
 
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S., Bouchaab H., Zimmerman S., Bucher M., Gaide O., Letovanec I., Homicsko K., Michielin O., 2014. Melanoma Research, 24 (5) pp. 496-500.
[DOI][WoS][Pmid][serval:BIB_FB42577CAC5A]
Standards of care and novel approaches in the management of glioblastoma multiforme.
Hottinger A.F., Stupp R., Homicsko K., 2014. Chinese Journal of Cancer, 33 (1) pp. 32-39. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCA412FE3838]
2013
 
PET Imaging in Glioma: The Neuro-Oncologist's Expectations.
Hottinger A.F., Levivier M., Negretti L., Homicsko K., Stupp R., 2013/04. PET clinics, 8 (2) pp. 117-128. Peer-reviewed.
[DOI][Pmid][serval:BIB_503994F97E67]
A colorectal cancer classification system that associates cellular phenotype and responses to therapy.
Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., Ostos L.C., Lannon W.A., Grotzinger C., Del Rio M. et al., 2013. Nature Medicine, 19 (5) pp. 619-625. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A29B5E2F4014]
2012
Decision making and management of gliomas: practical considerations.
Hottinger A.F., Homicsko K., Negretti L., Lhermitte B., Stupp R., 2012. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 23 Suppl 10 pp. x33-x40.
[URN][DOI][WoS][Pmid][serval:BIB_65E3046828D9]
2011
 
Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].
Berthod G., Homicsko K., Bouchaab H., Matter M., Cerottini J.P., Guggisberg D., Speiser D., Leyvraz S., Michielin O., 2011. Revue Médicale Suisse, 7 (296) pp. 1126-1130.
[Pmid][serval:BIB_6A4C636AAB5B]
 
Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K., Berthold D.R., 2011/01. Anti-cancer drugs, 22 Suppl 1 pp. S4-8. Peer-reviewed.
[DOI][Pmid][serval:BIB_73800E4C3E9E]
2008
 
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M., Carlisle R.C., Hernandez-Alcoceba R., Iggo R., Homicsko K., Fisher K.D., Halldén G., Mautner V., Shen Y., Seymour L.W., 2008/09. Human gene therapy, 19 (9) pp. 873-886. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2D8CA12E641D]
2006
Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C., Homicsko K., Lukashev A.N., Pittet A.L., Iggo R.D., 2006/10/04. BMC cancer, 6 p. 236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5AA4B76AFD3A]
2005
 
RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.
Homicsko K., Lukashev A., Iggo R.D., 2005/08/01. Cancer research, 65 (15) pp. 6882-6890. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_64BEEC50B3BD]
2003
 
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
Homicskó K.G., Kertész I., Radnai B., Tóth B.E., Tóth G., Fülöp F., Fekete M.I., Nagy G.M., 2003/01. Neurochemistry international, 42 (1) pp. 19-26. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_062C0DB9B653]
2002
 
Physiological role of salsolinol: its hypophysiotrophic function in the regulation of pituitary prolactin secretion.
Tóth B.E., Bodnár I., Homicskó K.G., Fülöp F., Fekete M.I., Nagy G.M., 2002. Neurotoxicology and teratology, 24 (5) pp. 655-666. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B7FF6A1C2647]
2001
 
Salsolinol is a putative endogenous neuro-intermediate lobe prolactin-releasing factor.
Tóth B.E., Homicskó K., Radnai B., Maruyama W., DeMaria J.E., Vecsernyés M., Fekete M.I., Fülöp F., Naoi M., Freeman M.E. et al., 2001/12. Journal of neuroendocrinology, 13 (12) pp. 1042-1050. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_066F2BB1E36C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University